ATH434 not checked
Alterity Therapeutics · PBT434
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Multiple System Atrophy
- Main trialPhase 2
- “This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.”In the company’s words, NCT07729852 on ClinicalTrials.gov
- Other names
- PBT434
Other drugs for Multiple System Atrophy
Coming up1
- Jul 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Enrolling by invitation | Jul 2029 | Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France | |
| Phase 2Completed | 28 Nov 2024 | Study of ATH434 in Participants with Multiple System Atrophy | |
| Phase 2Completed | 26 Feb 2025 | A Biomarker Study of ATH434 in Participants With MSA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026